Eicosapentaenoic Acid Could Permit Maintenance of the Original Ribavirin Dose in Chronic Hepatitis C Virus Patients during the First 12 Weeks of Combination Therapy with Pegylated Interferon-α and Ribavirin
Publisher: Karger
E-ISSN: 1423-0100|50|6|439-446
ISSN: 0300-5526
Source: Intervirology, Vol.50, Iss.6, 2008-02, pp. : 439-446
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract